Skip to content

Abstract 10036: Apolipoproteins and Cardiovascular-Kidney-Metabolic-Biomarkers Each Add to Prediction of Residual Cardiovascular Disease Risk After Acute Coronary Syndrome: Insights from the ODYSSEY OUTCOMES Trial

Nov 2026 · Circulation · Vol 154 · 0 citations

TL;DR

The conclusion that residual risk in ACS is multidimensional is supported, and comprehensive biomarker profiling with a multiplex apolipoprotein panel including apoE phenotypes and emerging CKM tests each provides clinically meaningful improvement in the prediction of MACE and death beyond conventional demographics, disease state and standard lipid profile.

Abstract

Background: Residual cardiovascular risk persists in acute coronary syndrome (ACS) despite intensive lipid-lowering therapy. We investigated whether extended biomarker profiling, including a 9-plex apolipoprotein panel (with apoE phenotyping) and 11 CE-marked emerging Cardiovascular-Kidney-Metabolic (CKM) parameters, improves prediction of major adverse cardiovascular events (MACE) and death beyond conventional demographic and lipid parameters in the ODYSSEY OUTCOMES trial. Methods: The trial was randomized, double-blind, and compared the PCSK9 inhibitor alirocumab to placebo in patients with recent ACS receiving optimized statin treatment. Over a median follow-up of 2.8 years, the primary MACE endpoint comprised coronary heart disease death, nonfatal myocardial infarction, fatal and nonfatal ischemic stroke, and hospitalization for unstable angina; all-cause death was a secondary endpoint. In 11,843 trial participants (placebo n=5926; alirocumab n=5917) apolipoproteins and apoE phenotype were measured by mass spectrometry and CKM parameters were measured using a Roche Cobas analyzer. CKM parameters included cystatin C, high-sensitivity troponin T (hs cTnT) , NT-proBNP, high-sensitivity C-reactive protein, small-dense low-density lipoprotein, GDF-15, sFlt, interleukin 6, insulin, homocysteine, and the NAFLD fibrosis score (Angulo et al . Hepatology . 2007;45:846-54). Incremental multivariable logistic regression models with natural cubic splines were constructed with demographics, diseases and standard lipid parameters (Model 1), apolipoprotein panel (Model 2), and CKM parameters (Model 3). Model performance was assessed using area under the curve (AUC) statistics, DeLong tests and generalized likelihood ratio tests. Due to lower event counts, penalized regression (ridge-type penalty) was applied for death analyses. Results: The baseline model yielded AUCs of 0.66 (0.64 - 0.68) for prediction of MACE and 0.71 (0.68 - 0.74) for death (Figure 1). Addition of apolipoproteins improved the AUCs to 0.69 (0.67 - 0.71) for MACE and 0.76 (0.72 - 0.79) for death. Further addition of CKM parameters improved the AUCs to 0.72 (0.70 - 0.75) and 0.82 (0.79 - 0.85), respectively. For MACE, the five strongest predictors were hs cTnT, apolipoprotein(a), NT-proBNP, diabetes, and cystatin C. For death, the five strongest predictors included NT-proBNP, sex, total cholesterol, age and small dense LDL-C. Conclusion: In statin-treated patients with recent ACS, comprehensive biomarker profiling with a multiplex apolipoprotein panel including apoE phenotypes and emerging CKM tests each provides clinically meaningful improvement in the prediction of MACE and death beyond conventional demographics, disease state and standard lipid profile. These findings support the conclusion that residual risk in ACS is multidimensional.

View source

Similar papers

Nov 2026

Abstract 16393: Cardiometabolic Therapy After PCI: Real-World Outcomes Associated with GLP-1 Receptor Agonist Use

Background: Patients undergoing percutaneous coronary intervention (PCI) remain at substantial risk for recurrent ischemic events despite advances in contemporary secondary prevention. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardiovascular benefits in patients with cardiometabolic dise...

Harsh Agarwal · 0 citations
Nov 2026

Abstract 8341: High-Sensitivity C-Reactive Protein, All-Cause Mortality and Heart Failure Hospitalization After Acute Coronary Syndrome in Type 2 Diabetes: Insights from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) Trial

Background: Patients with type 2 diabetes (T2D) remain at high risk for adverse outcomes after acute coronary syndrome (ACS). High-sensitivity C-reactive protein (hsCRP) may identify residual risk in this setting. Objective: To evaluate whether baseline hsCRP is associated with all-cause mortality (ACM) and he...

V. Anagnostopoulou, Guang K. Zhang, N. Girerd et al. · 0 citations
Nov 2026

Abstract 13281: High-Sensitivity C-Reactive Protein as a Cardiovascular Risk Factor in Cardiovascular-Kidney-Metabolic Syndrome, Independent of Low-Density Lipoprotein Cholesterol Level

Background: Cardiovascular-kidney-metabolic (CKM) syndrome integrates metabolic dysfunction, kidney impairment, and cardiovascular risk, yet systemic inflammation may independently drive CKM-related cardiovascular complications. High-sensitivity C-reactive protein (hsCRP) is widely used in clinical practice as a rob...

Xiao-Yu Ren, Ze-Yuan Wang, Jia-Hui Xiang et al. · 0 citations
Nov 2026

Abstract 10761: Cardiac Biomarkers, Cardiovascular and Kidney Outcomes in Type 2 Diabetes: A Post-Hoc Analysis of the Look AHEAD Cardiac Biomarker Ancillary Study

Background: In the Look AHEAD trial, an intensive lifestyle intervention (ILI) reduced the risk of chronic kidney disease (CKD) in type 2 diabetes (T2D). Adults with CKD have higher concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT). Whether CKD...

Zhi-Qi Yao, Kershaw V. Patel, K. Garcia et al. · 0 citations
Open access Oct 2026

One-Year Systolic Blood Pressure and Subsequent Cardiovascular Outcomes After Acute Coronary Syndrome: Insights from a Swiss Prospective Cohort.

AIMS Current guidelines recommend targeting systolic blood pressure (SBP) below 130 mmHg in patients at high cardiovascular risk, including after acute coronary syndrome (ACS), although evidence specific to the post-ACS setting remains limited. We evaluated the prognostic value of SBP measured 1 year after ACS on subse...

Henri Lu, C. Follonier, L. Artels et al. · 0 citations
Nov 2026

Abstract 13852: Time in Normal-High Potassium Range and Cardiovascular Outcomes in Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Analysis

Background: Serum potassium is a known prognostic marker in patients with heart failure (HF) and chronic kidney disease (CKD), with both hypo- and hyperkalemia associated with adverse outcomes. The POTCAST trial demonstrated that targeting a potassium range of 4.5-5.0 mmol/L may be optimal in patients at high risk f...

Henri Lu, B. Claggett, G. Filippatos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.